Chronic Pain Market to Expand Significantly by 2032, States DelveInsight Report | Paradigm Biopharmaceuticals, Noven Pharmaceuticals, GSK, Sustained Therapeutics Inc., Apurano Pharmaceuticals GmbH, Carolinas Pain Institute Beijing Konruns Pharmaceutical

DelveInsight's "Chronic Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chronic Pain, historical and forecasted epidemiology as well as the Chronic Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Pain Market Forecast
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Chronic Pain Market Report:
• The Chronic Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In April 2023, The US FDA has approved QULIPTA (atogepant), created by Allergan, now part of AbbVie, for preventing migraines in adults. Additionally, in August 2023, the European Commission approved AQUIPTA (atogepant) for migraine prophylaxis in adults experiencing four or more migraine days per month.
• In March 2023, The FDA in the United States gave its approval for Pfizer's ZAVZPRET (zavegepant), which is a third-generation, high-affinity, selective, and structurally distinctive small molecule CGRP receptor antagonist. This approval allows for the acute treatment of migraines in adults, whether with or without aura.
• In 2023, the total prevalence of chronic pain in the United States was approximately 54 million, with only about 36 million cases being diagnosed.
• In the seven major markets (7MM), the total diagnosed cases of chronic pain were approximately 114.4 million in 2023. According to the analysis, these cases are projected to grow by 2034 at a moderate compound annual growth rate (CAGR).
• In the United States, the 45-64 age group had the highest number of age-specific cases in 2023, with approximately 2.2 million diagnosed cases recorded within this particular age bracket.
• In 2023, the United States had the highest number of diagnosed chronic pain cases among Western countries, totaling approximately 36.2 million cases. It is anticipated that this number will rise by the conclusion of 2034.
• In cases of chronic pain, approximately 30% are diagnosed as mild, whereas around 70% are identified as severe.
• Key Chronic Pain Companies: Paradigm Biopharmaceuticals, Noven Pharmaceuticals, GSK, Sustained Therapeutics Inc., Apurano Pharmaceuticals GmbH, Carolinas Pain Institute Beijing Konruns Pharmaceutical, University of South Florida, AJU Pharm Co., Ltd., Massachusetts General Hospital, Apurano Pharmaceuticals, Persica Pharmaceuticals Ltd, Eli Lilly and Company, Vertanical GmbH, Fidia Farmaceutici s.p.a., Creative Medical Technology, Sorrento Therapeutics, Tissue Tech Inc., and others
• Key Chronic Pain Therapies: ZILOSUL (pentosan polysulfate sodium), HP-5000 (diclofenac sodium), GSK3858279, ST-01, Adezunap (AP707), Buprenorphine Buccal Film [Belbuca], Jincaopian Tablets, Exparel, OM-89 [Uro-Vaxom® Capsule], Siltuximab, Adezunap, PP353, GSK3858279, LY3016859 ISA, VER-01, Tricortin 1000, CELZ-201-DDT, Resiniferatoxin, TTAX03, and others
• The Chronic Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Pain pipeline products will significantly revolutionize the Chronic Pain market dynamics.

Chronic Pain Overview
Chronic pain is a long-term pain condition that persists for months or even years, often beyond the typical time expected for healing after an injury or illness. Unlike acute pain, which is a direct response to injury and resolves once the underlying cause is treated, chronic pain continues even after the initial cause has been addressed.

Get a Free sample for the Chronic Pain Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Pain Epidemiology Segmentation:
The Chronic Pain market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Chronic Pain
• Prevalent Cases of Chronic Pain by severity
• Gender-specific Prevalence of Chronic Pain
• Diagnosed Cases of Episodic and Chronic Chronic Pain

Download the report to understand which factors are driving Chronic Pain epidemiology trends @ Chronic Pain Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Pain market or expected to get launched during the study period. The analysis covers Chronic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Pain Therapies and Key Companies
• ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals
• HP-5000 (diclofenac sodium): Noven Pharmaceuticals
• GSK3858279: GSK
• ST-01: Sustained Therapeutics Inc.
• Adezunap (AP707): Apurano Pharmaceuticals GmbH
• Buprenorphine Buccal Film [Belbuca]: Carolinas Pain Institute
• Jincaopian Tablets: Beijing Konruns Pharmaceutical
• Exparel: University of South Florida
• OM-89 [Uro-Vaxom® Capsule]: AJU Pharm Co., Ltd.
• Siltuximab: Massachusetts General Hospital
• Adezunap: Apurano Pharmaceuticals
• PP353: Persica Pharmaceuticals Ltd
• GSK3858279: GlaxoSmithKline
• LY3016859 ISA: Eli Lilly and Company
• VER-01: Vertanical GmbH
• Tricortin 1000: Fidia Farmaceutici s.p.a.
• CELZ-201-DDT: Creative Medical Technology
• Resiniferatoxin: Sorrento Therapeutics
• TTAX03: Tissue Tech Inc.

Discover more about therapies set to grab major Chronic Pain market share @ Chronic Pain Treatment Landscape
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Pain Market Strengths
• According to the CDC, in the US itself around 50 million adults have chronic daily pain, with around 20 million adults experiencing high impact chronic pain that interferes with daily life or work activities, indicating the huge opportunity in this area
• Label expansion into the other indications also very much on the cards if the drug is able to show the efficacy in the range of opioids with better safety profile.

Chronic Pain Market Opportunities
• There is an implicit need of drugs which are pocket friendly, non-addictive, easy to administer and possess no side effects.
• More than 2/3rd of patients are suffering from moderate to severe chronic pain and opioids are the mainstay of treatment; majority of patients/ physicians are eagerly waiting for non-opioids options.

Scope of the Chronic Pain Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Pain Companies: Paradigm Biopharmaceuticals, Noven Pharmaceuticals, GSK, Sustained Therapeutics Inc., Apurano Pharmaceuticals GmbH, Carolinas Pain Institute Beijing Konruns Pharmaceutical, University of South Florida, AJU Pharm Co., Ltd., Massachusetts General Hospital, Apurano Pharmaceuticals, Persica Pharmaceuticals Ltd, Eli Lilly and Company, Vertanical GmbH, Fidia Farmaceutici s.p.a., Creative Medical Technology, Sorrento Therapeutics, Tissue Tech Inc., and others
• Key Chronic Pain Therapies: ZILOSUL (pentosan polysulfate sodium), HP-5000 (diclofenac sodium), GSK3858279, ST-01, Adezunap (AP707), Buprenorphine Buccal Film [Belbuca], Jincaopian Tablets, Exparel, OM-89 [Uro-Vaxom® Capsule], Siltuximab, Adezunap, PP353, GSK3858279, LY3016859 ISA, VER-01, Tricortin 1000, CELZ-201-DDT, Resiniferatoxin, TTAX03, and others
• Chronic Pain Therapeutic Assessment: Chronic Pain current marketed and Chronic Pain emerging therapies
• Chronic Pain Market Dynamics: Chronic Pain market drivers and Chronic Pain market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Pain Unmet Needs, KOL's views, Analyst's views, Chronic Pain Market Access and Reimbursement

To know more about Chronic Pain companies working in the treatment market, visit @ Chronic Pain Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Chronic Pain Market Report Introduction
2. Executive Summary for Chronic Pain
3. SWOT analysis of Chronic Pain
4. Chronic Pain Patient Share (%) Overview at a Glance
5. Chronic Pain Market Overview at a Glance
6. Chronic Pain Disease Background and Overview
7. Chronic Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Pain
9. Chronic Pain Current Treatment and Medical Practices
10. Chronic Pain Unmet Needs
11. Chronic Pain Emerging Therapies
12. Chronic Pain Market Outlook
13. Country-Wise Chronic Pain Market Analysis (2020-2034)
14. Chronic Pain Market Access and Reimbursement of Therapies
15. Chronic Pain Market Drivers
16. Chronic Pain Market Barriers
17. Chronic Pain Appendix
18. Chronic Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Chronic Pain Epidemiology https://www.delveinsight.com/report-store/chronic-pain-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chronic Pain Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Chronic Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Cart-related Neurotoxicity Market https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market
DelveInsight's "CART-related Neurotoxicity Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the CART-related Neurotoxicity, historical and forecasted epidemiology as well as the CART-related Neurotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

H3n2 Infection Market
https://www.delveinsight.com/report-store/h3n2-infection-market
DelveInsight's "H3N2 Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the H3N2 Infection, historical and forecasted epidemiology as well as the H3N2 Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.